A Study: Pure CBD as Single-agent for Solid Tumor.
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including
the cannabidiol (CBD) which does not posses the psychotropic effects of
D9-tetrahydrocannabinol (THC). These include anti-proliferative and pro-apoptotic effects and
they are known to interfere with several mechanisms in the tumorgenesis. Yet, evidence from
clinical trials among cancer patients is needed. The aim of the current study is to evaluate
the impact of CBD as single treatment among cancer patients.